Omics Based Clinical Trials Market Revenue Is Projected To Increase 2.2x Times Between 2022 And 2032

Omics Based Clinical Trials

The study on the Global Omics Based Clinical Trials Market Insights published by Fact.MR is a comprehensive analysis of the key factors that are likely to determine the growth of Omics Based Clinical Trials Market Insights in the upcoming years. Further, the study dives deep to investigate the micro and macro-economic parameters that are expected to influence the global scenario of the Omics Based Clinical Trials Market Insights during the forecast period.

The report examines the current trends, growth opportunities, restraints, and market drivers that are projected to influence the overall dynamics of the Omics Based Clinical Trials Market Insights in the assessment period.

Request Sample                          

Omics Based Clinical Trials Market Segmentation

  • By Phase Type :

    • Phase 1
    • Phase 2
    • Phase 3
    • Phase 4
  • By Study Design Type :

    • Interventional Studies
    • Observational Studies
    • Expanded Access Studies
  • By Indication :

    • Oncology
    • Cardiology
    • Respiratory Diseases
    • Skin Diseases
    • CNS Diseases
    • Immunology
    • Genetic Diseases
    • Other Indications
  • By Region :

    • North America
    • Latin America
    • Europe
    • APAC
    • MEA

Competitive Analysis

Due to the presence of a large number of developed as well as medium to small-sized organisations, the market for omics-based clinical trials is significantly competitive. A number of market participants are privately held or are part of the portfolios of private equity companies. Some of the key prominent players in the Omics Based Clinical Trials market include: Parexel International Corporation, Pharmaceutical Product Development (PPD), Charles River Laboratory, ICON plc, SGS SA, Eli Lilly and Company, Pfizer Inc., Covance Inc., Novo Nordisk, Rebus Bio.

Some of the recent developments of key Omics Based Clinical Trials providers are as follows:

  • In December 2021, Rebus Biosystems Inc., a life science technology firm based in the U.S., stated that it had acquired the assay assets and IP of EEL Transcriptomics AB, a privately held company focused on high-plex spatial transcriptomics with single-cell resolution.
  • In November 2021, ICON plc announced that its Accellacare Site Network had grown in reach and capabilities as a result of new relationships with six research sites in four countries.
  • In February 2021, Parexel and Neo Genomics established a strategic alliance in precision medicine with the goal of improving study designs and speeding up patient matching in oncology clinical trials.
  • In March 2019, Mission Bio and Labcorp teamed to use single-cell genomics to expedite targeted medication development.